BIOGEN INC (IDP.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:IDP - US09062X1037 - Common Stock
148.6 EUR
+8.05 (+5.73%)
We assign a fundamental rating of 6 out of 10 to IDP. IDP was compared to 86 industry peers in the Biotechnology industry. IDP gets an excellent profitability rating and is at the same time showing great financial health properties. IDP is valued quite cheap, but it does not seem to be growing. These ratings would make IDP suitable for value investing!
1. Profitability
1.1 Basic Checks
- In the past year IDP was profitable.
- IDP had a positive operating cash flow in the past year.
- IDP had positive earnings in each of the past 5 years.
- IDP had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- IDP has a better Return On Assets (5.51%) than 82.56% of its industry peers.
- Looking at the Return On Equity, with a value of 8.84%, IDP belongs to the top of the industry, outperforming 82.56% of the companies in the same industry.
- IDP's Return On Invested Capital of 9.70% is amongst the best of the industry. IDP outperforms 87.21% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for IDP is in line with the industry average of 11.58%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROIC | 9.7% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
- With an excellent Profit Margin value of 15.98%, IDP belongs to the best of the industry, outperforming 82.56% of the companies in the same industry.
- In the last couple of years the Profit Margin of IDP has declined.
- IDP has a Operating Margin of 28.50%. This is amongst the best in the industry. IDP outperforms 86.05% of its industry peers.
- IDP's Operating Margin has declined in the last couple of years.
- IDP's Gross Margin of 75.24% is fine compared to the rest of the industry. IDP outperforms 67.44% of its industry peers.
- IDP's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
- IDP has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- Compared to 1 year ago, IDP has more shares outstanding
- The number of shares outstanding for IDP has been reduced compared to 5 years ago.
- Compared to 1 year ago, IDP has an improved debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 3.26 indicates that IDP is not in any danger for bankruptcy at the moment.
- IDP has a Altman-Z score of 3.26. This is in the better half of the industry: IDP outperforms 73.26% of its industry peers.
- IDP has a debt to FCF ratio of 2.78. This is a good value and a sign of high solvency as IDP would need 2.78 years to pay back of all of its debts.
- IDP's Debt to FCF ratio of 2.78 is amongst the best of the industry. IDP outperforms 83.72% of its industry peers.
- IDP has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.
- With a Debt to Equity ratio value of 0.35, IDP perfoms like the industry average, outperforming 58.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 3.26 |
ROIC/WACC1.16
WACC8.36%
2.3 Liquidity
- IDP has a Current Ratio of 2.72. This indicates that IDP is financially healthy and has no problem in meeting its short term obligations.
- IDP has a Current ratio (2.72) which is comparable to the rest of the industry.
- A Quick Ratio of 2.04 indicates that IDP has no problem at all paying its short term obligations.
- The Quick ratio of IDP (2.04) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 |
3. Growth
3.1 Past
- IDP shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.51%.
- The earnings per share for IDP have been decreasing by -13.31% on average. This is quite bad
- Looking at the last year, IDP shows a small growth in Revenue. The Revenue has grown by 4.77% in the last year.
- The Revenue has been decreasing by -7.62% on average over the past years.
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
3.2 Future
- Based on estimates for the next years, IDP will show a small growth in Earnings Per Share. The EPS will grow by 0.59% on average per year.
- IDP is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.63% yearly.
EPS Next Y-7.54%
EPS Next 2Y-3.12%
EPS Next 3Y-0.66%
EPS Next 5Y0.59%
Revenue Next Year1.93%
Revenue Next 2Y-1.65%
Revenue Next 3Y-1.2%
Revenue Next 5Y-0.63%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 10.42, which indicates a very decent valuation of IDP.
- Based on the Price/Earnings ratio, IDP is valued cheaply inside the industry as 95.35% of the companies are valued more expensively.
- IDP's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.32.
- A Price/Forward Earnings ratio of 11.28 indicates a reasonable valuation of IDP.
- Based on the Price/Forward Earnings ratio, IDP is valued cheaper than 96.51% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 24.32. IDP is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.42 | ||
| Fwd PE | 11.28 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, IDP is valued cheaper than 93.02% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, IDP is valued cheaper than 95.35% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.31 | ||
| EV/EBITDA | 7.53 |
4.3 Compensation for Growth
- The decent profitability rating of IDP may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.12%
EPS Next 3Y-0.66%
5. Dividend
5.1 Amount
- IDP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:IDP (1/22/2026, 7:00:00 PM)
148.6
+8.05 (+5.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30 2025-10-30/bmo
Earnings (Next)02-06 2026-02-06/amc
Inst Owners96.04%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap21.80B
Revenue(TTM)10.07B
Net Income(TTM)1.61B
Analysts73.33
Price Target163.18 (9.81%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)4.97%
PT rev (3m)10.15%
EPS NQ rev (1m)0.42%
EPS NQ rev (3m)-54.28%
EPS NY rev (1m)0.27%
EPS NY rev (3m)-5.93%
Revenue NQ rev (1m)-0.09%
Revenue NQ rev (3m)-2.47%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)1.53%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.42 | ||
| Fwd PE | 11.28 | ||
| P/S | 2.54 | ||
| P/FCF | 11.31 | ||
| P/OCF | 10.43 | ||
| P/B | 1.41 | ||
| P/tB | 10.73 | ||
| EV/EBITDA | 7.53 |
EPS(TTM)14.26
EY9.6%
EPS(NY)13.17
Fwd EY8.86%
FCF(TTM)13.14
FCFY8.84%
OCF(TTM)14.25
OCFY9.59%
SpS58.45
BVpS105.73
TBVpS13.85
PEG (NY)N/A
PEG (5Y)N/A
Graham Number184.18
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROCE | 11.07% | ||
| ROIC | 9.7% | ||
| ROICexc | 11.44% | ||
| ROICexgc | 40.96% | ||
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% | ||
| FCFM | 22.48% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Debt/EBITDA | 1.73 | ||
| Cap/Depr | 25.04% | ||
| Cap/Sales | 1.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 67.56% | ||
| Profit Quality | 140.63% | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 | ||
| Altman-Z | 3.26 |
F-Score5
WACC8.36%
ROIC/WACC1.16
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
EPS Next Y-7.54%
EPS Next 2Y-3.12%
EPS Next 3Y-0.66%
EPS Next 5Y0.59%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
Revenue Next Year1.93%
Revenue Next 2Y-1.65%
Revenue Next 3Y-1.2%
Revenue Next 5Y-0.63%
EBIT growth 1Y15.15%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year6.14%
EBIT Next 3Y0.99%
EBIT Next 5Y1.51%
FCF growth 1Y120.5%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.46%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%
BIOGEN INC / IDP.DE FAQ
What is the ChartMill fundamental rating of BIOGEN INC (IDP.DE) stock?
ChartMill assigns a fundamental rating of 6 / 10 to IDP.DE.
What is the valuation status for IDP stock?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (IDP.DE). This can be considered as Undervalued.
What is the profitability of IDP stock?
BIOGEN INC (IDP.DE) has a profitability rating of 7 / 10.
What is the financial health of BIOGEN INC (IDP.DE) stock?
The financial health rating of BIOGEN INC (IDP.DE) is 7 / 10.
What is the expected EPS growth for BIOGEN INC (IDP.DE) stock?
The Earnings per Share (EPS) of BIOGEN INC (IDP.DE) is expected to decline by -7.54% in the next year.